Induction Methotrexate, Cisplatin, and 5-Fluorouracil Versus Cisplatin and 5-Fluorouracil Followed by Radiotherapy in Pediatric Nasopharyngeal CarcinomaCitation formats

  • External authors:
  • Abdelatif Al Mousa
  • Ramiz Abu-Hijlih
  • Iyad Sultan
  • Layth Mula-Hussain
  • Taleb Ismael
  • Issa Mohamad

Standard

Induction Methotrexate, Cisplatin, and 5-Fluorouracil Versus Cisplatin and 5-Fluorouracil Followed by Radiotherapy in Pediatric Nasopharyngeal Carcinoma : A Retrospective Analysis in a Tertiary Cancer Center. / Al Mousa, Abdelatif; Abu-Hijlih, Ramiz; Salem, Ahmed; Sultan, Iyad; Mula-Hussain, Layth; Ismael, Taleb; Mohamad, Issa.

In: Journal of pediatric hematology/oncology, Vol. 39, No. 8, 01.11.2017, p. e437-e442.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Al Mousa, Abdelatif ; Abu-Hijlih, Ramiz ; Salem, Ahmed ; Sultan, Iyad ; Mula-Hussain, Layth ; Ismael, Taleb ; Mohamad, Issa. / Induction Methotrexate, Cisplatin, and 5-Fluorouracil Versus Cisplatin and 5-Fluorouracil Followed by Radiotherapy in Pediatric Nasopharyngeal Carcinoma : A Retrospective Analysis in a Tertiary Cancer Center. In: Journal of pediatric hematology/oncology. 2017 ; Vol. 39, No. 8. pp. e437-e442.

Bibtex

@article{9caf4572013c4b7d81a21115502650f2,
title = "Induction Methotrexate, Cisplatin, and 5-Fluorouracil Versus Cisplatin and 5-Fluorouracil Followed by Radiotherapy in Pediatric Nasopharyngeal Carcinoma: A Retrospective Analysis in a Tertiary Cancer Center",
abstract = "PURPOSE: The purpose of this study is to compare treatment outcomes of methotrexate, cisplatin, and 5-fluorouracil (MPF) or cisplatin and 5-fluorouracil (PF) in pediatric NPC patients treated with sequential chemoradiotherapy.PATIENTS AND METHODS: A total of 25 patients aged 18 years or below with stage II-IV NPC treated with IC using PF (n=16) or MPF (n=9) followed by radiotherapy between 2003 and 2009 were retrospectively reviewed. Radiotherapy dose was 61.2 to 66.6 Gy to the gross disease. Age, stage, radiation dose, and chemotherapy regimen were tested as prognostic factors for event-free survival (EFS) and overall survival (OS) on univariate and multivariate analyses.RESULTS: The median age at diagnosis was 13.3 years. All patients completed planned chemotherapy. All patients who received MPF achieved PR whereas 15 patients (93.8%) who received PF achieved PR (P=1). There were no differences in EFS (68.75% vs. 66.67%; P=0.84) and OS (81.25% vs. 66.67%; P=0.39) at 5 years between PF and MPF, respectively. On multivariate analysis, only tumor stage (IV vs. II-III) predicted worse OS (hazard ratio, 10.3; 95% confidence interval, 1.197-88.974) but not EFS (hazard ratio, 4.805; 95% confidence interval, 0.95-24.336). Distant metastases was the predominant site of failure, seen in 5 patients (20%).CONCLUSIONS: Omission of methotrexate from the induction chemotherapy regimen did not affect treatment outcome.",
author = "{Al Mousa}, Abdelatif and Ramiz Abu-Hijlih and Ahmed Salem and Iyad Sultan and Layth Mula-Hussain and Taleb Ismael and Issa Mohamad",
year = "2017",
month = nov,
day = "1",
doi = "10.1097/MPH.0000000000000933",
language = "English",
volume = "39",
pages = "e437--e442",
journal = "Journal of pediatric hematology/oncology",
issn = "1077-4114",
publisher = "Lippincott Williams & Wilkins",
number = "8",

}

RIS

TY - JOUR

T1 - Induction Methotrexate, Cisplatin, and 5-Fluorouracil Versus Cisplatin and 5-Fluorouracil Followed by Radiotherapy in Pediatric Nasopharyngeal Carcinoma

T2 - A Retrospective Analysis in a Tertiary Cancer Center

AU - Al Mousa, Abdelatif

AU - Abu-Hijlih, Ramiz

AU - Salem, Ahmed

AU - Sultan, Iyad

AU - Mula-Hussain, Layth

AU - Ismael, Taleb

AU - Mohamad, Issa

PY - 2017/11/1

Y1 - 2017/11/1

N2 - PURPOSE: The purpose of this study is to compare treatment outcomes of methotrexate, cisplatin, and 5-fluorouracil (MPF) or cisplatin and 5-fluorouracil (PF) in pediatric NPC patients treated with sequential chemoradiotherapy.PATIENTS AND METHODS: A total of 25 patients aged 18 years or below with stage II-IV NPC treated with IC using PF (n=16) or MPF (n=9) followed by radiotherapy between 2003 and 2009 were retrospectively reviewed. Radiotherapy dose was 61.2 to 66.6 Gy to the gross disease. Age, stage, radiation dose, and chemotherapy regimen were tested as prognostic factors for event-free survival (EFS) and overall survival (OS) on univariate and multivariate analyses.RESULTS: The median age at diagnosis was 13.3 years. All patients completed planned chemotherapy. All patients who received MPF achieved PR whereas 15 patients (93.8%) who received PF achieved PR (P=1). There were no differences in EFS (68.75% vs. 66.67%; P=0.84) and OS (81.25% vs. 66.67%; P=0.39) at 5 years between PF and MPF, respectively. On multivariate analysis, only tumor stage (IV vs. II-III) predicted worse OS (hazard ratio, 10.3; 95% confidence interval, 1.197-88.974) but not EFS (hazard ratio, 4.805; 95% confidence interval, 0.95-24.336). Distant metastases was the predominant site of failure, seen in 5 patients (20%).CONCLUSIONS: Omission of methotrexate from the induction chemotherapy regimen did not affect treatment outcome.

AB - PURPOSE: The purpose of this study is to compare treatment outcomes of methotrexate, cisplatin, and 5-fluorouracil (MPF) or cisplatin and 5-fluorouracil (PF) in pediatric NPC patients treated with sequential chemoradiotherapy.PATIENTS AND METHODS: A total of 25 patients aged 18 years or below with stage II-IV NPC treated with IC using PF (n=16) or MPF (n=9) followed by radiotherapy between 2003 and 2009 were retrospectively reviewed. Radiotherapy dose was 61.2 to 66.6 Gy to the gross disease. Age, stage, radiation dose, and chemotherapy regimen were tested as prognostic factors for event-free survival (EFS) and overall survival (OS) on univariate and multivariate analyses.RESULTS: The median age at diagnosis was 13.3 years. All patients completed planned chemotherapy. All patients who received MPF achieved PR whereas 15 patients (93.8%) who received PF achieved PR (P=1). There were no differences in EFS (68.75% vs. 66.67%; P=0.84) and OS (81.25% vs. 66.67%; P=0.39) at 5 years between PF and MPF, respectively. On multivariate analysis, only tumor stage (IV vs. II-III) predicted worse OS (hazard ratio, 10.3; 95% confidence interval, 1.197-88.974) but not EFS (hazard ratio, 4.805; 95% confidence interval, 0.95-24.336). Distant metastases was the predominant site of failure, seen in 5 patients (20%).CONCLUSIONS: Omission of methotrexate from the induction chemotherapy regimen did not affect treatment outcome.

UR - http://www.scopus.com/inward/record.url?scp=85032708123&partnerID=8YFLogxK

U2 - 10.1097/MPH.0000000000000933

DO - 10.1097/MPH.0000000000000933

M3 - Article

C2 - 28816803

AN - SCOPUS:85032708123

VL - 39

SP - e437-e442

JO - Journal of pediatric hematology/oncology

JF - Journal of pediatric hematology/oncology

SN - 1077-4114

IS - 8

ER -